Neuroendocrine differentiation in prostatic malignancy

Cancer

Volumn 78, Issue 2, 1996, Pages 357-361

  Di Sant'Agnese, P Anthony ^a   Cockett, Abraham T K ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE HORMONE; SEROTONIN;

APUD CELL; CARCINOID; CELL DIFFERENTIATION; CONFERENCE PAPER; NEUROENDOCRINE SYSTEM; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SMALL CELL CARCINOMA;

APUD CELLS; CARCINOID TUMOR; CARCINOMA; CARCINOMA, SMALL CELL; CELL DIFFERENTIATION; CELL DIVISION; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH SUBSTANCES; HORMONES; HUMANS; MALE; NEUROENDOCRINE TUMORS; NEUROSECRETORY SYSTEMS; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SEROTONIN;

EID: 0029680203     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960715)78:2<357::AID-CNCR27>3.0.CO;2-U     Document Type: Conference Paper

References (32)

1. Wingo T, Tong T, Bolden S. Cancer Statistics, 1995. CA Center J Clin 1995; 45:8-30.
2. Steiner M. Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol 1995; 153:1085-96.
3. di Sant'Agnese P. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications. Cancer 1992; 70:254-68.
4. di Sant'Agnese P. Neuroendocrine differentiation in prostatic carcinoma. Recent findings and new concepts. Cancer 1995; 75:1850-59.
5. di Sant'Agnese P, de Mesy Jensen K. Somatostatin and/ or somatostatin-like immunoreactive endocrine-paracrine cells in the human prostate gland. Arch Pathol Lab Med 1984; 108:693-6.
6. di Sant'Agnese PA. Calcitonin-like immunoreactive and bombesin-like immunoreactive endocrine-paracrine cells of the human prostate. Arch Pathol Lab Med 1986; 110:412-5.
7. Fetissof F, Arbeille B, Guilloteau D, Lanson Y. Glycoprotein hormone a-chain-immunoreactive endocrine cells in prostate and cloacal derived tissues. Arch Pathol Lab Med 1987; 111:836-40.
8. di Sant'Agnese P, de Mesy Jensen K. Calcitonin, katacalcin and calcitonin gene-related peptide in the human prostate: an immunocytochemical and immunoelectron microscopic study. Arch Pathol Lab Med 1989; 113:790-6.
9. Abrahamsson PA, Lilja H. Partial characterization of a thyroid-stimulating hormone-like peptide in neuroendocrine cells of the human prostate gland. Prostate 1989; 14:71-81.
10. Iwamura M, Wu G, Abrahamsson PA, di Sant'Agnese P, Cockett A, Deftos L. Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells. Urology 1994; 43:667-74.
11. Schmid K, Helpap B, Totsch M, Kirchmair M, Dockhorn-Dworniczak B, Bucker W, et al. Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic and neoplastic prostate. Histopathology 1994; 24:233-9.
12. Iwamura M, Benning C, diSant'Agnese P, Cockett A, Wu G, Gershagen S. Overexpression of human epidermal growth factor and c-cerbB-2 by neuroendocrine cells in normal prostatic tissue. Urology 1994; 43:838-43.
13. Cohen R, Glezerson O, Haffejee Z. Neuro-endocrine cells: a new prognostic parameter in prostate cancer. Br J Urol 1991; 68:258-62.
14. Epstein J, Partin A, Veltri R. Neuroendocrine differentiation (NE) in prostate cancer: enhanced prediction of progression following radical prostatectomy. Lab Invest 1995; 72:75A.
15. Grignon D, Caplan R, Sakr W, Porter A, Doggen RLS, John M, Abrams R, Lawton C. Neuroendocrine (NE) differentiation as a prognostic indicator in locally advanced prostate cancer (PCa). Lab Invest 1995; 72:76A.
16. Aprikian A, Cordon-Cardo C, Fan W, Reuter V. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993; 71: 3952-65.
17. Allen F, VanVelden D, Heyns. Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer? Br J Urol 1995; 75:751-4.
18. Adlakha H, Bostwick C. Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases. Hum Pathol 1994; 25:135-9.
19. Tarle M, Rados N. Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring; comparative study of a multiple tumor marker assay. Prostate 1991; 19:23.
20. Kadmon D, Thompson T, Lynch G, Scardino P. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 1991; 146:358-61.
21. Lauder J. Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci 1993; 16:233-40.
22. Dalsgaard C, Hultgardh A, Haegerstrand A, Nilsson J. Neuropeptides as growth factors: possible roles in human diseases. Regul Pept 1989; 25:1-9.
23. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomeni M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989; 63:1714-20.
24. Iwamura M, Wu G, Abrahamsson PA, Cockett A, Foss K, Deftos L. Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 1994; 43:675-9.
25. Shah G, Rayford W, Noble M, Austenfeld M, Weigel J, Vamos S, et al. Calcitonin stimulates growth of human prostate cancer cells through receptor-mediated increase in cyclic adenosine 3′,5′-monophosphates and cytoplasmic Ca2 transients. Endocrinology 1994; 134:596-602.
26. Bonkoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic and neoplastic human prostate. Prostate 1991; 19:91-8.
27. Segal N, Cohen F, Huffejee Z, Savage N. BCL-2 protooncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Path Lab Med 1994; 118:616-8.
28. Bonkhoff H, Stein U, Remberger K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic and neoplastic human prostate. Virchows Arch A Pathol Anat 1993; 423:291-4.
29. Krijnen J, Janssen P, Ruizveld de Winter J, can Kimpen H, Schroder F, vander Kwast T. Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 1993; 100:393-8.
30. Prevost G, Mormont C, Gunning M, Thomas F. Therapeutic use and perspectives of synthetic peptides in oncology. Acta Oncologica 1994; 32:209-15.
31. Oberg K, Eriksson B, Janson E. Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors. Digestion 1994; 55(Suppl)64-9.
32. Bejetta E, Di Bartolomeo M, Zilembo N, Bochicchio M. Medical treatment of neuroendocrine tumors. Tumori 1993; 79:380-8.